本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、2025 年第二次临时股东大会（以下简称"本次股东大会"）召开期间未出 现否决议案的情形； 2、本次股东大会不涉及变更以往股东大会已通过的决议。 3、本次股东大会采取现场投票和网络投票相结合的方式召开。 证券代码：002551 证券简称：尚荣医疗 公告编号：2025-059 深圳市尚荣医疗股份有限公司 2025 年第二次临时股东大会决议公告 一、会议召开及出席情况 （一）会议召开情况 1、会议召集人：公司董事会。 2、会议时间： （1）现场会议召开时间：2025年12月29日（星期一）下午14:30； （2）网络投票时间：2025年12月29日 其中，通过深圳证券交易所交易系统进行网络投票的时间为2025年12月29 日的交易时间即：9:15—9:25，9:30—11:30和13:00—15:00；通过深圳证券交易 所互联网投票系统投票的时间为2025年12月29日上午9:15至下午15:00 期间任意 时间。 3、现场会议召开地点：深圳市龙岗区宝龙工业城宝龙5路2号尚荣科技工业 园公司会议室。 ...

法律意见书 广东华商律师事务所 关于深圳市尚荣医疗股份有限公司 2025年第二次临时股东大会的 法律意见书 二○二五年十二月二十九日 1 法律意见书 致：深圳市尚荣医疗股份有限公司 广东华商律师事务所（以下简称"本所"）接受深圳市尚荣医疗股份有限公 司（以下简称"公司"）的委托，指派本所周玉梅律师、邓娇律师（以下简称"本 所律师"）出席公司2025年第二次临时股东大会（以下简称"本次会议"）。本 所律师依据《中华人民共和国证券法》（以下简称"《证券法》"）、《中华人 民共和国公司法》（以下简称"《公司法》"）、《上市公司股东会规则》等法 律、法规和规范性法律文件以及《深圳市尚荣医疗股份有限公司章程》（以下简 称"《公司章程》"）的规定，出具本法律意见书。 经本所律师核查，公司本次会议于2025年12月29日下午14：30在深圳市龙岗 区宝龙工业城宝龙5路2号尚荣科技工业园尚荣医疗会议室召开，会议由公司董事 2 法律意见书 长梁桂秋先生主持，会议召开的时间、地点、审议事项与《股东大会通知》所告 知的内容一致。本次会议采取现场投票与网络投票相结合的方式，公司通过深圳 证券交易所交易系统和互联网投票系统（http: ...

Core Viewpoint - Shangrong Medical (002551) has experienced a significant decline in both revenue and net profit for the first three quarters of 2025, indicating potential challenges in its business operations and financial health [2]. Financial Performance - For the first three quarters of 2025, Shangrong Medical reported a total revenue of 754 million yuan, a year-on-year decrease of 24.85% [2]. - The net profit attributable to shareholders was -35.13 million yuan, reflecting a year-on-year decline of 338.5% [2]. - The net profit after deducting non-recurring items was -42.33 million yuan, down 1336.59% year-on-year [2]. - In Q3 2025, the company recorded a quarterly revenue of 225 million yuan, a decrease of 39.25% compared to the same quarter last year [2]. - The quarterly net profit attributable to shareholders was -27.37 million yuan, a decline of 4004.28% year-on-year [2]. - The quarterly net profit after deducting non-recurring items was -29.81 million yuan, down 2776.04% year-on-year [2]. - The company's debt ratio stands at 23.31%, with investment income of 10.20 million yuan and financial expenses of -3.79 million yuan [2]. - The gross profit margin is reported at 14.35% [2]. Stock Performance - As of December 26, 2025, Shangrong Medical's stock closed at 3.7 yuan, down 1.07% with a turnover rate of 1.34% [1]. - The trading volume was 81,900 hands, with a total transaction value of 30.45 million yuan [1]. - On December 26, the net inflow of main funds was 2.63 million yuan, accounting for 8.64% of the total transaction value, while retail investors saw a net outflow of 1.74 million yuan, representing 5.7% of the total transaction value [1].

Group 1 - The core point of the article highlights that Shangrong Medical (002551) experienced a stock price increase of 1.63% to 3.74 yuan as of December 25, 2025, with a trading volume of 73,200 hands and a total transaction amount of 27.16 million yuan [1] - On December 25, the net inflow of main funds was 2.38 million yuan, accounting for 8.78% of the total transaction amount, while retail investors saw a net outflow of 2.18 million yuan, representing 8.01% of the total transaction amount [1][2] - The company's Q3 2025 report indicates a significant decline in revenue, with a total revenue of 755.4 million yuan, down 24.85% year-on-year, and a net profit attributable to shareholders of -35.13 million yuan, a decrease of 338.5% [2] Group 2 - In Q3 2025, the company's single-quarter revenue was 225 million yuan, reflecting a year-on-year decrease of 39.25%, and the net profit attributable to shareholders was -27.37 million yuan, down 4004.28% [2] - The company's debt ratio stands at 23.31%, with investment income of 10.20 million yuan and financial expenses of -3.79 million yuan, while the gross profit margin is reported at 14.35% [2]

Group 1 - The core viewpoint of the article highlights the financial performance of Shangrong Medical (002551) as of December 24, 2025, showing a significant decline in revenue and net profit compared to the previous year [2][3] - As of December 24, 2025, Shangrong Medical's stock closed at 3.68 yuan, with a trading volume of 66,800 hands and a total transaction amount of 24.64 million yuan [1] - The company's main business includes the production and sales of medical products, medical services, and health industry operations [2] Group 2 - For the first three quarters of 2025, Shangrong Medical reported a main revenue of 754 million yuan, a year-on-year decrease of 24.85% [2] - The net profit attributable to the parent company for the same period was -35.13 million yuan, reflecting a year-on-year decline of 338.5% [2] - The third quarter of 2025 saw a single-quarter main revenue of 225 million yuan, down 39.25% year-on-year, and a net profit of -27.37 million yuan, a decrease of 4004.28% year-on-year [2]

Core Viewpoint - Shangrong Medical (002551) has experienced significant declines in revenue and net profit for the first three quarters of 2025, indicating potential challenges in its business operations and financial health [2]. Financial Performance - For the first three quarters of 2025, Shangrong Medical reported a main revenue of 754 million yuan, a year-on-year decrease of 24.85% [2]. - The net profit attributable to shareholders was -35.13 million yuan, reflecting a year-on-year decline of 338.5% [2]. - The net profit after deducting non-recurring items was -42.33 million yuan, down 1336.59% year-on-year [2]. - In Q3 2025, the company recorded a single-quarter main revenue of 225 million yuan, a decrease of 39.25% compared to the same quarter last year [2]. - The single-quarter net profit attributable to shareholders was -27.37 million yuan, a decline of 4004.28% year-on-year [2]. - The single-quarter net profit after deducting non-recurring items was -29.81 million yuan, down 2776.04% year-on-year [2]. - The company's debt ratio stands at 23.31%, with investment income of 10.20 million yuan and financial expenses of -3.79 million yuan [2]. - The gross profit margin is reported at 14.35% [2]. Market Activity - As of December 19, 2025, Shangrong Medical's stock closed at 3.75 yuan, up 1.35% with a turnover rate of 1.78% [1]. - The trading volume was 108,700 hands, with a total transaction amount of 40.43 million yuan [1]. - On December 19, the net outflow of main funds was 2.99 million yuan, accounting for 7.39% of the total transaction amount, while retail investors saw a net inflow of 5.46 million yuan, representing 13.51% of the total transaction amount [1].

Core Viewpoint - The stock of Shangrong Medical (002551) has shown a decline in both price and financial performance, indicating potential challenges in the company's operations and market position [1][3]. Financial Performance - As of December 16, 2025, Shangrong Medical's stock closed at 3.59 yuan, down 1.37% with a trading volume of 87,300 hands and a transaction amount of 31.4656 million yuan [1]. - The company reported a net profit of -35.1253 million yuan for the first three quarters of 2025, a year-on-year decrease of 338.5% [3]. - The third quarter of 2025 saw a single-quarter revenue of 22.5 million yuan, down 39.25% year-on-year, with a net profit of -27.367 million yuan, reflecting a significant decline of 4004.28% [3]. Market Position - Shangrong Medical's total market capitalization is 3.035 billion yuan, significantly lower than the industry average of 10.661 billion yuan, ranking 101 out of 125 in the medical device industry [3]. - The company's net asset value stands at 2.73 billion yuan, compared to the industry average of 3.883 billion yuan, ranking 57 out of 125 [3]. - The company's gross margin is 14.35%, which is substantially below the industry average of 51.02%, ranking 120 out of 125 [3]. Capital Flow - On December 16, 2025, the net outflow of main funds was 1.1352 million yuan, accounting for 3.61% of the total transaction amount, while retail investors saw a net inflow of 1.9253 million yuan, representing 6.12% of the total transaction amount [1][2]. - Over the past five days, the stock has experienced fluctuating capital flows, with notable net outflows from main and speculative funds on several days [2].

Core Viewpoint - The stock of Shangrong Medical (002551) has shown a decline in both price and financial performance, indicating potential challenges in the medical device industry [1][3]. Financial Performance - As of December 12, 2025, Shangrong Medical's stock closed at 3.61 yuan, down 1.1% with a trading volume of 118,900 shares and a turnover of 43.236 million yuan [1]. - For the first three quarters of 2025, the company's main revenue was 754 million yuan, a year-on-year decrease of 24.85%, and the net profit attributable to shareholders was -35.1253 million yuan, a decline of 338.5% [3]. - The third quarter alone saw a revenue of 225 million yuan, down 39.25% year-on-year, with a net profit of -27.367 million yuan, a staggering drop of 4004.28% [3]. Market Position and Ratios - Shangrong Medical's total market capitalization is 3.052 billion yuan, significantly lower than the industry average of 10.776 billion yuan, ranking 101 out of 125 in the medical device sector [3]. - The company has a negative price-to-earnings ratio of -65.17, while the industry average is 68.3, indicating poor profitability [3]. - The gross margin stands at 14.35%, compared to the industry average of 51.02%, ranking 120 out of 125 [3]. Capital Flow Analysis - On December 12, 2025, the net outflow of main funds was 1.4042 million yuan, accounting for 3.25% of the total turnover, while retail investors saw a net inflow of 1.582 million yuan, representing 3.66% of the total turnover [1][2]. - Over the past five days, the trend shows consistent net outflows from main and speculative funds, with retail investors being the only group showing net inflows [2].

《关于续聘会计师事务所的公告》 《尚荣医疗财务负责人管理制度》 《尚荣医疗子公司管理制度》 《尚荣医疗内部控制制度》 《尚荣医疗内部审计制度》 《尚荣医疗防范控股股东、实际控制人及其他关联方占用公司资金制度》 《尚荣医疗信息披露重大差错责任追究制度》 《尚荣医疗信息披露管理制度》 《尚荣医疗内幕信息知情人登记制度》 《尚荣医疗投资者关系管理制度》 《尚荣医疗重大信息内部报告制度》 《尚荣医疗舆情管理制度》 《尚荣医疗董事会秘书工作细则》 《尚荣医疗董事会战略决策委员会议事规则》 《尚荣医疗董事会审计委员会议事规则》 《尚荣医疗董事会提名委员会议事规则》 《尚荣医疗董事会薪酬与考核委员会议事规则》 《尚荣医疗重大财务决策制度》 《尚荣医疗重大生产经营决策制度》 《尚荣医疗独立董事工作制度》 《尚荣医疗董事会议事规则》 《尚荣医疗股东会议事规则》 《尚荣医疗信息披露暂缓与豁免管理制度》 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 《尚荣医疗重大投资决策制度》 《尚荣医疗募集资金管理制度》 《尚荣医疗对外担保管理办法》 《尚荣医疗关联 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002551 证券简称：尚荣医疗公告编号：2025-053 深圳市尚荣医疗股份有限公司 第八届董事会第十一次临时会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、董事会会议召开情况 深圳市尚荣医疗股份有限公司（以下简称"公司"或"尚荣医疗"）第八届董事会第十一次临时会议，于 2025年12月8日以书面、传真及电子邮件的方式发出会议通知和会议议案，并于2025年12月10日在公司 以现场加通讯（通讯方式参加人员为虞熙春、曾江虹、赵俊峰、龙琼）相结合的方式召开，本次会议应 参加表决权董事9名，实际参加表决权董事9名。公司监事均列席了会议。会议由董事长梁桂秋先生主 持，会议的召集和召开符合《中华人民共和国公司法》及《公司章程》的规定。 二、董事会会议审议情况 经与会董事认真审议，并以记名投票的方式，形成如下决议： （一）审议通过了《关于公司控股子公司向建设银行申请贷款授信额度的议案》 鉴于原额度已到期，因生产经营需要，公司控股子公司合肥普尔德医疗用品有限公司（公司持有其股权 55%，以下简称 ...